Nikolai Kragøe Andresen
6PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Aug 25, 2025
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy.Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen
|Nov 15, 2024
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold
|Jul 09, 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials.Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen
|Apr 23, 2024
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation.Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen
|Jan 19, 2024
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur
|Dec 09, 2022
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Annette Bjerre
Pageof 1
